M ore than 3 million people in the United States are chronically infected with the hepatitis C virus (HCV). 1, 2 Although the number of new infections has been declining for decades, HCV-related morbidity and mortality are projected to continue rising for another 20 years. 3 One half to three quarters of persons currently infected with HCV have not received a diagnosis and are untreated; many will have progression to decompensated cirrhosis, hepatocellular carcinoma, and other liver complications. 3, 4 Early diagnosis and treatment are essential to improve long-term health outcomes in this population. New guidelines from the Centers for Disease Control and Prevention and the U.S. Community Preventive Services Task Force have broadened recommendations for screening to include all adults born between 1945 and 1965. 5, 6 To accompany this expanded screening program, there is a recognized need for a simple, safe regimen of short duration that can provide high cure rates in a broad range of patients. 7 Sofosbuvir (Gilead Sciences), an oral nucleotide analogue inhibitor of the HCV-specific NS5B polymerase, has recently been approved for the treatment of chronic HCV infection. 8 The labeled use for patients with HCV genotype 1 infection is sofosbuvir with peginterferon alfa and ribavirin for 12 weeks, or sofosbuvir plus ribavirin for 24 weeks in patients who are ineligible to receive interferon therapy. Ledipasvir (Gilead Sciences) is a new HCV NS5A inhibitor with demonstrated antiviral activity against HCV genotypes 1a and 1b. 9 In the phase 2 LONESTAR trial, patients with HCV genotype 1 infection without cirrhosis who received 8 or 12 weeks of ledipasvir-sofosbuvir, with or without ribavirin, had rates of sustained virologic response of 95 to 100%. 10 The phase 3 ION-1 and ION-2 trials (also reported in the Journal) 11, 12 showed that 12 weeks of treatment with ledipasvir-sofosbuvir was associated with response rates that were similar to those among patients who received 24 weeks of treatment.
We conducted a phase 3 trial involving previously untreated patients with HCV genotype 1 infection without cirrhosis to explore the feasibility of shortening the treatment duration. We assessed the single-tablet regimen of ledipasvirsofosbuvir administered for 8 weeks, with or without ribavirin (Ribasphere, Kadmon Pharmaceuticals), as compared with ledipasvir-sofosbuvir alone administered for 12 weeks.
ME THODS

PATIENTS
Patients were enrolled between May 20, 2013, and June 19, 2013, at 58 sites in the United States. Eligible patients were 18 years of age or older, with chronic HCV genotype 1 infection without cirrhosis, who had not received treatment for HCV infection previously. Patients were required to have an HCV RNA level of at least 10 4 IU per milliliter at the time of screening, alanine and aspartate aminotransferase levels of no more than 10 times the upper limit of the normal range, a platelet count of more than 90,000 per cubic millimeter, and a hemoglobin level of at least 11 g per deciliter (in women) or at least 12 g per deciliter (in men). There were no upper limits on age or body-mass index. Full eligibility criteria, including details of the assessment of the absence of cirrhosis, are provided in the study protocol, available with the full text of this article at NEJM.org. All the patients provided written informed consent.
STUDY DESIGN
In this multicenter, randomized, open-label trial, all the patients received a fixed-dose combination tablet containing 90 mg of ledipasvir and 400 mg of sofosbuvir, administered orally once daily. Ribavirin was administered orally twice daily, with the dose determined according to body weight (1000 mg daily in patients with a body weight of <75 kg, and 1200 mg daily in patients with a body weight of ≥75 kg).
Patients were randomly assigned in a 1:1:1 ratio to one of three treatment groups: ledipasvirsofosbuvir for 8 weeks, ledipasvir-sofosbuvir plus ribavirin for 8 weeks, or ledipasvir-sofosbuvir for 12 weeks. Randomization was stratified according to HCV genotype (1a or 1b).
STUDY ASSESSMENTS
The primary efficacy end point was an HCV RNA level of less than 25 IU per milliliter at 12 weeks after the end of therapy (sustained virologic response). This end point was assessed in all the patients who underwent randomization and received at least one dose of a study drug. In the primary efficacy analysis, the rate of sustained virologic response in each of the three treatment groups was compared with a calculated historical response rate of 60%. A key secondary end point was the noninferiority of 8 weeks 3 of ledipasvir-sofosbuvir to the other treatment regimens.
Screening assessments included measurement of the serum HCV RNA level and IL28B (rs12979860) genotyping, as well as standard laboratory and clinical tests. The serum HCV RNA level was measured with the COBAS TaqMan HCV Test, version 2.0, for use with the High Pure System (Roche Molecular Systems), which has a lower limit of quantification of 25 IU per milliliter. HCV genotype and subtype were determined with the use of the Versant HCV Genotype INNO-LiPA 2.0 assay (Siemens Healthcare Diagnostics).
Assessments during treatment included standard laboratory testing, measurement of the serum HCV RNA level, vital signs, electrocardiography, and symptom-directed physical examinations. All adverse events were recorded and graded according to a standardized scale (see the study protocol).
Deep sequencing of the NS5A and NS5B regions of the HCV RNA was performed in all the patients at baseline, and again at the time of failure in those who had virologic failure. The resulting sequences were compared to detect resistance-associated variants that emerged during treatment. We report resistance-associated variants that were present in more than 1% of sequence reads.
STUDY OVERSIGHT
This trial was approved by the institutional review board or independent ethics committees at each participating site and was conducted in compliance with the principles of the Declaration of Helsinki, Good Clinical Practice guidelines, and local regulatory requirements. The study was designed and conducted according to the protocol by the sponsor (Gilead Sciences) in collaboration with the principal investigators. The sponsor collected the data, monitored the study conduct, and performed the statistical analyses. An independent data and safety monitoring committee reviewed the progress of the study. The investigators, participating institutions, and sponsor agreed to maintain confidentiality of the data. All the authors had access to the data and assume responsibility for the integrity and completeness of the reported data. The manuscript was prepared by a medical writer who was an employee of the sponsor, with input from all the authors. The first author made the decision to submit the manuscript for publication.
STATISTICAL ANALYSIS
The Kruskal-Wallis test was used to test for overall differences in continuous variables across treatment groups; the Cochran-Mantel-Haenszel test was used to test for overall differences in categorical variables across treatment groups. We determined that a sample of 200 patients in each treatment group would provide the study with more than 90% power to detect an improvement of at least 30 percentage points in the rate of sustained virologic response, as compared with a calculated control rate of 60%. This 60% rate was based on rates of sustained virologic response in phase 3 trials of telaprevir 13 and boceprevir, 14 allowing for a rate of sustained virologic response that was 5 percentage points lower than the adjusted rate of 65%, in exchange for an expected improved safety profile and shorter duration of treatment. The comparison with the calculated control rate was performed with the use of a two-sided, exact one-sample binomial test at a significance level of 0.025. In addition, noninferiority between the groups was assessed with the use of the conventional confidence-interval approach and a noninferiority margin of 12 percentage points. For details concerning the calculation of the control rate and the noninferiority margin, see the Supplementary Appendix, available at NEJM.org. The two-sided 95% exact confidence interval calculated by the Clopper-Pearson method is provided for the rate of sustained virologic response at 12 weeks after the end of treatment in each of the three treatment groups and in all patient subgroups.
R ESULT S
BASELINE CHARACTERISTICS
Of the 831 patients who were initially screened, 647 underwent randomization and began treatment ( Fig. S1 in the Supplementary Appendix). Most of the patients who were screened but not enrolled were excluded for not meeting eligibility criteria (Table S1 in the Supplementary Appendix). The demographic and baseline clinical characteristics of the patients were generally balanced among the three treatment groups ( Table  1) (6) 15 (7) * Plus-minus values are means ±SD. The Kruskal-Wallis test was used to test for overall differences in continuous variables across treatment groups; the Cochran-Mantel-Haenszel test was used to test for overall differences in categorical variables across treatment groups. There were no significant differences (at the significance level of 0.05) among the treatment groups with regard to any of the baseline characteristics. HCV denotes hepatitis C virus, LDV ledipasvir, RBV ribavirin, SOF sofosbuvir, and ULN upper limit of the normal range. † The body-mass index is the weight in kilograms divided by the square of the height in meters. ‡ Race and ethnic group were self-reported. § The presence of fibrosis was determined by means of liver biopsy (Metavir stage, on a scale from F0 to F4, with higher stages indicating a greater degree of fibrosis). No patient in this study had a fibrosis score of F4. ¶ Interferon eligibility was determined by the site investigator on the basis of whether, in the investigator's judgment, the patient had contraindications to interferon therapy. Table 2 ).
In the secondary analysis of noninferiority, the rate of sustained virologic response among patients who received 8 weeks of ledipasvirsofosbuvir without ribavirin was noninferior to the response rates in the other two treatment groups, as evidenced by the fact that the lower boundaries of the confidence intervals for the difference in proportions between the groups were greater than the prespecified noninferiority margin of −12 percentage points. As compared with the rate of sustained virologic response in the group that received 8 weeks of ledipasvirsofosbuvir, the rate in the group that received 12 weeks of ledipasvir-sofosbuvir was 1 percentage point higher (97.5% CI, −4 to 6) and the rate in the group that received 8 weeks of ledipasvirsofosbuvir with ribavirin was 1 percentage point lower (95% CI, −6 to 4) ( Table S3 in the Supplementary Appendix) .
The patients' responses according to baseline characteristics are shown in Figure 1 , and in Table S2 in the Supplementary Appendix. The rates of sustained virologic response in prespecified subgroups across the three treatment groups were generally similar to those observed in the overall population. Patients with characteristics historically associated with a poor response to interferon-based treatment -non-CC IL28B genotype, high viral load at baseline, black race, and HCV genotype 1a infection -had rates of sustained virologic response that were similar to the rates among patients without these characteristics. Among patients who received 8 weeks of ledipasvir-sofosbuvir alone, the rates of response in all the subgroups ranged from 89% to 100%. The fibrosis score (which was used as a measure of liver damage) had no discernible effect on the rate of sustained virologic response at post-treatment week 12 (Table S7 in the Supplementary Appendix). Among the 647 patients treated, no patient had virologic breakthrough during study treatment. Overall, 23 patients had a virologic relapse after the end of therapy: 11 patients (5%) in the group that received 8 weeks of ledipasvir-sofosbuvir, 9 (4%) in the group that received 8 weeks of ledipasvir-sofosbuvir plus ribavirin, and 3 (1%) in the 12-week group. The characteristics of the patients who had a relapse are provided in Table  S4 in the Supplementary Appendix. The majority of these patients were, like the majority of patients in the study population, non-Hispanic white men with HCV genotype 1a infection.
VIROLOGIC RESISTANCE TESTING
Variants associated with resistance to NS5A inhibitors were detected at baseline by means of deep sequencing in 116 of the 647 patients (18%) for whom data were available. Of the 116 patients, 104 (90%) had a sustained virologic response. Of the 23 patients who had a relapse, 15 had NS5A resistance-associated variants at the The position of the square indicates the rate of sustained virologic response at 12 weeks after the end of treatment in each subgroup; the horizontal lines indicate 95% confidence intervals. The vertical lines represent the overall rate of sustained virologic response in each treatment group. Race or ethnic group was self-reported. Data from patients with other (i.e., nonwhite and nonblack) race, unreported ethnic group, and unconfirmed HCV genotype (1a or 1b) are not included. Interferon eligibility was determined by the site investigator on the basis of whether, in the investigator's judgment, the patient had contraindications to interferon therapy. The body-mass index is the weight in kilograms divided by the square of the height in meters. HCV denotes hepatitis C virus, LDV ledipasvir, RBV ribavirin, SOF sofosbuvir, and ULN upper limit of the normal range.
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time of relapse and 8 did not. Of the 15 patients with NS5A resistance-associated variants at relapse, 9 had the variants at baseline and 6 did not. The NS5B S282T variant, which is associated with reduced susceptibility to sofosbuvir, was not detected by means of deep sequencing in any patient at baseline or at the time of virologic failure (Table S6 in the Supplementary Appendix).
SAFETY
Of the 647 patients in the study, 3 discontinued ledipasvir-sofosbuvir prematurely owing to adverse events: 1 patient in the group that received 8 weeks of ledipasvir-sofosbuvir plus ribavirin (owing to a road accident), and 2 in the group that received 12 weeks of ledipasvir-sofosbuvir (1 owing to arthralgia and 1 owing to lung cancer). A total of 10 patients had serious adverse events; no single serious adverse event occurred in more than 1 patient. A full list of serious adverse events is provided in Table S5 in the Supplementary Appendix. Fatigue, headache, and nausea were the most common adverse events. The incidence of adverse events was lower among patients receiving ledipasvir-sofosbuvir alone (67% and 69% of patients receiving 8 weeks and 12 weeks of treatment, respectively) than among those receiving 8 weeks of ledipasvir-sofosbuvir plus ribavirin (76%) ( Table 3) . Patients in the group that received ledipasvir-sofosbuvir plus ribavirin had higher rates of events that are generally associated with (5) 26 (12) 15 (7) Irritability 3 (1) 29 (13) 9 (4) Diarrhea 15 (7) 13 (6) 9 (4) Arthralgia 9 (4) 11 (5) 16 (7) Constipation 9 (4) 13 (6) 8 (4) Dizziness 6 (3) 13 (6) 9 (4) Rash 3 (1) 19 (9) 5 (2) Pruritus 2 (1) 16 (7) 5 (2) Cough 3 (1) 12 (6) 7 (3) Anemia 2 (1) 17 (8) 2 (1) Muscle spasms 3 (1) 11 (5) 6 ( ribavirin therapy -fatigue, headache, nausea, insomnia, irritability, rash, pruritus, cough, and anemia -than did patients who received ledipasvir-sofosbuvir alone (Table 3) . 15 A total of 2 patients (1%) receiving 8 weeks of ledipasvirsofosbuvir, 8 (4%) receiving 8 weeks of ledipasvir-sofosbuvir plus ribavirin, and 7 (3%) receiving 12 weeks of ledipasvir-sofosbuvir had grade 3 (severe) or grade 4 (life-threatening) adverse events. In the groups that received 8 weeks of treatment, the mean change in the hemoglobin level from baseline to week 8 was −0.2 g per deciliter among those who received ledipasvir-sofosbuvir alone and −1.9 g per deciliter among those who received ledipasvir-sofosbuvir plus ribavirin. Patients in the 12-week group had a mean change in the hemoglobin level of −0.4 g per deciliter from baseline to week 12. A total of 11 patients (5%) in the group that received 8 weeks of ledipasvir-sofosbuvir plus ribavirin had a reduction in the hemoglobin level during treatment to less than 10 g per deciliter, as compared with no patients in the group that received 8 weeks of ledipasvir-sofosbuvir alone and 1 (<1%) in the group that received 12 weeks of ledipasvirsofosbuvir. A total of 3 patients (1%) who received 8 weeks of ledipasvir-sofosbuvir plus ribavirin had grade 3 hyperbilirubinemia; no other grade 3 or 4 hyperbilirubinemia occurred in any treatment group. The rates of laboratory abnormalities were otherwise similar among the three treatment groups (Table S8 in the Supplementary Appendix).
DISCUSSION
In this phase 3 trial, all three groups of previously untreated patients with HCV genotype 1 infection without cirrhosis who received treatment with ledipasvir-sofosbuvir had rates of sustained virologic response that were higher than 90%. The results of the noninferiority analysis suggested that adding ribavirin to the 8-week regimen of ledipasvir-sofosbuvir or extending the duration of treatment with ledipasvir-sofosbuvir from 8 weeks to 12 weeks did not result in improved rates of sustained virologic response.
In these previously untreated patients without cirrhosis, the rates of response were high in all patient subgroups and did not vary substantially according to patients' demographic or clinical characteristics at baseline, including characteristics historically associated with a poor response to interferon-based treatment. This uniformity of response suggests that the regimen of ledipasvirsofosbuvir may be appropriate for a broad range of previously untreated patients, reducing the need to tailor the regimen according to the characteristics of individual patients. Although relapse was more common among patients who received 8 weeks of treatment than among those who received 12 weeks of treatment, the small numbers of patients who had a relapse were not sufficient to identify baseline characteristics or response variables during treatment that were associated with relapse (Table S4 in the Supplementary Appendix).
Variants associated with resistance to NS5A inhibitors were detected at baseline by means of deep sequencing in 116 of the 647 patients (18%) for whom data were available; of these 116 patients, 104 (90%) had a sustained virologic response. The presence of any given NS5A resistance-associated variant at baseline was not associated with relapse. Variants associated with resistance to NS5A inhibitors developed in most but not all the patients who had a relapse. An ongoing trial in which patients who did not have a response to an 8-week or 12-week regimen of ledipasvir-sofosbuvir are retreated with ledipasvirsofosbuvir for 24 weeks (ClinicalTrials.gov number, NCT01987453) may provide further insight into the clinical significance of NS5A resistanceassociated variants for this particular regimen.
The results of this phase 3 study exploring the efficacy of an 8-week regimen for the treatment of HCV infection appear to support the rationale for the development of this regimen -namely, that two direct-acting antiviral agents with distinct viral targets and mechanisms of action can provide high efficacy and complementary resistance profiles. The rapidity and durability of viral suppression attained with this regimen appear to allow a shorter course of treatment for previously untreated patients without cirrhosis than has proved possible with interferon-based regimens. The feasibility of a regimen shorter than 8 weeks has been explored previously in the Electron trial, in which a group of previously untreated patients with HCV genotype 1 infection received 6 weeks of treatment with ledipasvirsofosbuvir plus ribavirin. 16 The result -17 of the 25 patients treated (68%) had a sustained virologic response, and 8 (32%) had a relapse after
